WebDec 5, 2024 · Hepatocellular Carcinoma (HCC) is one of the most common liver cancers and is often caused by long-term damage or scarring of the liver (liver cirrhosis). It is estimated to be responsible for 500,000 deaths every year. For various reasons, including the overall health of the patient, sometimes HCC cannot be treated with surgery. WebThe survival benefit of adjuvant transarterial chemoembolization (TACE) in patients with hepatectomy for hepatocellular carcinoma (HCC) after hepatectomy remains controversial. We aimed to investigate the survival efficacy of adjuvant TACE after hepatectomy for HCC.
Chemoembolization for Hepatocellular Carcinoma: …
WebMar 20, 2024 · Transcatheter arterial chemoembolisation (TACE), also known as transarterial chemoembolisation, is a minimally-invasive method of administrating … WebApr 18, 2024 · Purpose: To investigate clinical outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) using HepaSpheres 20–40 µm in diameter and … fda bioengineered food labeling 2022
Comparison of Microwave Ablation and Transarterial Chemoembolization …
WebJun 24, 2013 · Several therapeutic options have been advocated to treat HCC, including transcatheter arterial chemoembolization (TACE), surgical resection, and radiofrequency ablation. TACE has been widely used in the treatment of HCC by interrupting the arterial supply to the tumor, thus leading to ischemic tumor necrosis [ 15 ]. WebJan 19, 2024 · 380 Background: LAUNCH is a multicenter, randomized, open-label, parallel-group phase 3 trial, aiming to assess the efficacy and safety of lenvatinib plus TACE compared with lenvatinib alone as first-line therapy in patients with advanced hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC were randomly assigned in a … WebDec 7, 2024 · Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. Hepatocellular carcinoma is now the third leading cause of cancer deaths worldwide, … fda birth control guide